News

Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript
Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations, for his opening remarks. Thank you. Welcome to the Sandoz Q1 ...
Devdiscourse6d
Global Health Issues and Industry Responses: A Comprehensive Overview
This collection of health news covers a range of topics including criticisms of EU drug price proposals, new agreements ...
Drug Store News6d
Sandoz inks license agreement with Henlius for Yervoy biosimilar
Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...
Nasdaq5d
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
mid single-digit net-sales growth[1] and core EBITDA margin of around 21% Richard Saynor, Chief Executive Officer of Sandoz, commented: “With Q1 sales in line with our expectations, we have now ...
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to ...
Le Lézard5d
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million  up by 3% in constant currencies (cc); stable in USDup by 5%[1] at a ...